四川省人民医院Sichuan Provincial People's Hospital

该疾病的证据

依据官方公开数据来源筛选

1. Colorectal cancer

   Chengdu 成都市

   已发表研究

   • Dual-Energy CT-Derived Extracellular Volume Fraction for Prediction of Recurrence in Rectal Cancer: A Bicenter Study. Academic radiology, 2026
   • CT-derived extracellular volume fraction and AI-assisted body composition for predicting neoadjuvant therapy response and prognosis in colorectal cancer. Abdominal radiology (New York), 2026

   另有 2 项已发表研究

   PubMed 收录了 4 篇关于该疾病、并提及这家医院的论文。

   同时上榜：在复旦榜中为 Ophthalmology 获提名。

2. Breast cancer

   Chengdu 成都市

   已发表研究

   • Biomaterial-based mitochondria-targeted nanomedicine for remodeling the breast cancer tumor microenvironment and overcoming therapy resistance. Critical reviews in oncology/hematology, 2026
   • An endoplasmic reticulum-enriched nanogel couples ferroptotic tumor damage with macrophage reprogramming for triple-negative breast cancer immunotherapy. Bioactive materials, 2027

   PubMed 收录了 2 篇关于该疾病、并提及这家医院的论文。

   同时上榜：在复旦榜中为 Ophthalmology 获提名。

3. Lung cancer

   Chengdu 成都市

   已发表研究

   • Efbemalenograstim alfa as prophylaxis for chemotherapy-induced neutropenia in patients with non-small-cell lung cancer: a randomized, multicenter, phase II trial. Cancer biology & medicine, 2026
   • Pragmatic Screening for Sarcopenia in Non-Small Cell Lung Cancer: Development and Internal Validation of a Prospective Risk Model Integrating T12 CT Indices and Routine Clinical Variables. Cancer medicine, 2026

   另有 1 项已发表研究

   PubMed 收录了 3 篇关于该疾病、并提及这家医院的论文。

   同时上榜：在复旦榜中为 Ophthalmology 获提名。

4. Liver cancer

   Chengdu 成都市

   已发表研究

   • Mint3 suppresses cuproptosis by modulating the AHR signalling pathway to facilitate the progression of hepatocellular carcinoma. Science China. Life sciences, 2026
   • Magnetoreceptor Promotes Hepatocellular Carcinoma Development and Blunts Sorafenib-Induced Ferroptosis by Regulating Iron Homeostasis. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026

   另有 2 项已发表研究

   PubMed 收录了 4 篇关于该疾病、并提及这家医院的论文。

   同时上榜：在复旦榜中为 Ophthalmology 获提名。

5. Stomach cancer

   Chengdu 成都市

   已发表研究

   • Cancer-associated fibroblast-enriched TAGLN orchestrates HGF/c-MET-dependent transcriptional reprogramming in gastric cancer. Cancer letters, 2026

   PubMed 收录了 1 篇关于该疾病、并提及这家医院的论文。

   同时上榜：在复旦榜中为 Ophthalmology 获提名。

6. Prostate cancer

   Chengdu 成都市

   已发表研究

   • Development and validation of machine learning prognostic models for overall survival in non-surgical prostate cancer patients with bone metastases. The aging male : the official journal of the International Society for the Study of the Aging Male, 2026
   • Interpretable machine learning for individualized survival prediction in node-positive, non-metastatic prostate cancer: a population-based study. The aging male : the official journal of the International Society for the Study of the Aging Male, 2026

   PubMed 收录了 2 篇关于该疾病、并提及这家医院的论文。

   同时上榜：在复旦榜中为 Ophthalmology 获提名。

7. Nasopharyngeal carcinoma

   Chengdu 成都市

   已发表研究

   • Targeting FDX1 with oridonin triggers cuproptosis and inhibits tumor progression in nasopharyngeal carcinoma. The international journal of biochemistry & cell biology, 2026
   • Application of delta radiomics based on cone-beam computed tomography in predicting radiotherapy efficacy for nasopharyngeal carcinoma. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2026

   PubMed 收录了 2 篇关于该疾病、并提及这家医院的论文。

   同时上榜：在复旦榜中为 Ophthalmology 获提名。

8. Senile cataract

   Chengdu 成都市

   复旦专科声誉排行榜 2023

   • Ophthalmology 获提名 https://rank.cn-healthcare.com/fudan/specialty-reputation/year/2023/sid/4